Human Mesenchymal Stem Cell Secretome Increases Catalase In Wistar Rats With Cholestasis
International Journal of Drug Delivery Technology · 06.04.2026 · 16 (02)
DOI: 10.25258/ijddt.16.2.51 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 06.04.2026. Verfasst von Naufal Faruq Purwanto und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Cirrhosis represents the end stage of chronic liver disease and remains a major cause of morbidity and mortality worldwide. While liver transplantation is the only curative option, limited donor availability and high costs restrict accessibility. Ursodeoxycholic acid (UDCA) is often used to delay disease progression, but its regenerative capacity is limited. Mesenchymal stem cells (MSCs) and their secretome have been proposed as novel therapies, primarily through their paracrine antioxidant, anti-inflammatory, and anti-apoptotic effects. Oxidative stress plays a central role in cholestasis, and catalase serves as a critical enzyme in counteracting hydrogen peroxide–induced injury. This study aimed to investigate the effect of human MSC-secretome (HuMSC-S) on catalase levels in a rat model of cholestasis.
Methods
Twenty-four male Wistar rats (200–250 g) underwent common bile duct ligation to induce cholestasis and were randomly assigned into four groups: K1 (control), K2 (UDCA 4.5 mg/week), K3 (HuMSC-S 0.2 ml/kg/week), and K4 (UDCA + HuMSC-S). Interventions were administered for 4 weeks. Catalase levels were measured using ELISA. Statistical analysis included Shapiro–Wilk for normality, one-way ANOVA, and post hoc LSD test.
Results
Catalase activity significantly differed among groups (p < 0.001). The control group (1.46 ± 0.06 U/mL) showed the lowest levels. UDCA increased catalase to 4.89 ± 0.16 U/mL, while HuMSC-S further enhanced it to 6.79 ± 0.41 U/mL. The combination group demonstrated the highest activity (7.99 ± 0.29 U/mL), significantly exceeding all other groups.
Conclusion
HuMSC-S administration significantly enhanced catalase levels in cholestatic rats, with the greatest effect achieved in combination with UDCA. These findings suggest a synergistic antioxidant and hepatoprotective effect, supporting the therapeutic potential of MSC-secretome as a promising adjunct to conventional therapy.
Zitieren
APA
Purwanto, N. F., Prasetyo, S. A., & Najatullah, N. (2026). Human Mesenchymal Stem Cell Secretome Increases Catalase In Wistar Rats With Cholestasis. International Journal of Drug Delivery Technology, 16(02). https://doi.org/10.25258/ijddt.16.2.51
Vancouver
Purwanto NF, Prasetyo SA, Najatullah N. Human Mesenchymal Stem Cell Secretome Increases Catalase In Wistar Rats With Cholestasis. International Journal of Drug Delivery Technology. 2026;16(02). doi:10.25258/ijddt.16.2.51
BibTeX
@article{Purwanto2026,
author = {Purwanto, Naufal Faruq and Prasetyo, Sigit Adi and Najatullah, Najatullah},
title = {Human Mesenchymal Stem Cell Secretome Increases Catalase In Wistar Rats With Cholestasis},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {02},
doi = {10.25258/ijddt.16.2.51}
}
EUVIMED